Hypertensive Intracerebral Hemorrhage Of Symptomatic Deep Venous Thrombosis Anticoagulant Therapy

Objective: To evaluate the efficacy and safety of anticoagulation treatment ofsymptomatic deep venous thrombosis of hypertensive cerebral hemorrhage. Methods:65cases of patients with symptomatic deep venous thrombosis of hypertensive cerebralhemorrhage, including24cases after their family’s consent given low molecular weightheparin as A group,41cases without low molecular weight heparin therapy were taken asB group, compared the clinical effects of two groups. Results: there were statisticallysignificant differences between A group and B group in therapeutic effect(P=0.033), thetreatment group and the control group had significant difference in edema subsidingtime(P=0.017), the treatment group edema subsiding faster than the control group; nosignificant difference between the two groups in platelet count and coagulation function,the difference between the two groups and no complications such as bleeding andpulmonary embolism statistical significance. Conclusion: anticoagulant therapy aftercerebral hemorrhage4days can relatively safe and effective reduce hospitalization time inpatients with symptomatic deep venous thrombosis in hypertensive cerebral hemorrhage.